Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arzneiwerk AG VIDAFRA:TLIK +0.98%40 EV-to-EBIT is -4.91 as of Aug. 30, 2026. GuruFocus rates FRA:TLIK with a GF Score™ of 40/100. The stock has 7 warning signs investors should review. Among 98 Medical Distribution companies, Arzneiwerk AG VIDA ranks worse than 1020407.14% on this metric.
Arzneiwerk AG VIDA (FRA:TLIK) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Arzneiwerk AG VIDA's Enterprise Value for the quarter that ended in Mar. 2026 was €1.59 Mil.
Arzneiwerk AG VIDA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arzneiwerk AG VIDA EV-to-EBIT Related Terms
Arzneiwerk AG VIDA EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Arzneiwerk AG VIDA's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Arzneiwerk AG VIDA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arzneiwerk AG VIDA EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arzneiwerk AG VIDA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Arzneiwerk AG VIDA's EV-to-EBIT falls into.
Arzneiwerk AG VIDA's current Enterprise Value is €1.25 Mil.
Arzneiwerk AG VIDA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arzneiwerk AG VIDA (FRA:TLIK) has a EV-to-EBIT of -4.91 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arzneiwerk AG VIDA and its competitors. According to the industry distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 98 companies in the Medical Distribution industry.
Is Arzneiwerk AG VIDA's EV-to-EBIT too high?
Arzneiwerk AG VIDA's current EV-to-EBIT is -4.91. Based on the distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 98 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 98 companies for EV-to-EBIT. This places Arzneiwerk AG VIDA in the lower half of its industry. The industry median EV-to-EBIT is 11.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.49, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arzneiwerk AG VIDA and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arzneiwerk AG VIDA's current EV-to-EBIT is -4.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (FRA:TLIK) has a current EV-to-EBIT of -4.91. The current EV-to-EBIT is -4.91. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Arzneiwerk AG VIDA (FRA:TLIK), the current EV-to-EBIT is -4.91 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score
Get the complete analysis for FRA:TLIK
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TLIK has been successfully added to your 
